Incidence of pediatric invasive pneumococcal disease in the Island of Majorca (2008-2010), an area with non-universal vaccination, and estimations of serotype & children population coverage by available conjugate vaccines
| Autor: | Juan J. Picazo, Emma Padilla, Andres-Ricardo Perez, César Balseiro, Susana Herrero, Carmen Gallegos, Joaquin Dueñas, Esther Culebras, Antonio Ramirez, Cristina Méndez |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Male
Serotype medicine.medical_specialty Pediatrics Population humanos PCV13 medicine.disease_cause PCV10 Incidence rate vacunas antineumocócicas Pneumococcal Infections Pneumococcal Vaccines vacunación Medical microbiology estudios prospectivos Streptococcus pneumoniae Medicine Humans Prospective Studies Serotyping vacunas Child education education.field_of_study Vaccines lactante Vaccines Conjugate business.industry Incidence (epidemiology) Vaccination Infant Invasive pneumococcal disease PCV7 medicine.disease Majorca Pneumococcal infections Infectious Diseases Immunization Spain serotipificación Child Preschool Female infecciones neumocócicas business Research Article |
| Zdroj: | BMC Infectious Diseases |
| ISSN: | 1471-2334 |
| DOI: | 10.1186/1471-2334-13-503 |
| Popis: | Background: The World Health Organization reported in 2007 that inclusion of PCV7 in national immunization programs should be seen as a priority, also encouraging countries to conduct appropriate surveillances for monitoring the impact of vaccination. These analyses should be conducted in specific geographical areas and should be aimed to evolution of invasive pneumococcal disease (IPD), by age groups, clinical presentation, and vaccine serotypes (and non-vaccine serotypes to detect possible replacement). This study aimed to monitor the evolution of IPD incidence in children 59 months. By study year, IRs were 21.25 in 2008, 19.89 in 2009 and 9.80 in 2010. The reduction found in 2010 was significant and due to significant reductions in IRs of IPDs caused by serotypes included in PCV10 and PCV13. Overall, estimated serotype coverage by conjugate vaccines was 12.1% for PCV7, 37.9% for PCV10 and 65.2% for PCV13. Of the 66 hospitalized children with IPD, 20 had received at least one dose of PCV7 (13 cases with identified serotype). None of these 13 cases was caused by PCV7 serotypes, all were caused by PCV13 serotypes and only 53.8% by PCV10 serotypes. Conclusions: The results of the present study evidence the importance of expanding the number of serotypes covered by PCV, and the added value of PCV13 with respect to PCV10 and PCV7, even in an area of low prevalence of 19A as the Island of Majorca. This study was supported in part by an unrestricted grant from Pfizer S.L.U., Madrid, Spain. The sponsor had not role in analysis and interpretation of data, and in the decision to submit the article for publication. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|